ZA200109610B - Benzothiazinone and benzoxazinone compounds. - Google Patents

Benzothiazinone and benzoxazinone compounds.

Info

Publication number: ZA200109610B
Authority: ZA; South Africa
Prior art keywords: benzothiazinone; benzoxazinone compounds; benzoxazinone; compounds
Prior art date: 1999-06-03

Application number

ZA200109610A

Other languages

English (en)

Inventor

Paul Rafferty

Lee D Arnold

Jose L Ortego Matinez

Isabel F Fernandez

David Calderwood

Beatriz Gonzalez Pascual

Maria J Perez De Vega

Original Assignee

Knoll Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-06-03

Filing date

2001-11-21

Publication date

2003-04-30

2001-11-21 Application filed by Knoll Gmbh filed Critical Knoll Gmbh

2003-04-30 Publication of ZA200109610B publication Critical patent/ZA200109610B/xx

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
- C07D265/36—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Immunology (AREA)
Diabetes (AREA)
Endocrinology (AREA)
Physical Education & Sports Medicine (AREA)
Cardiology (AREA)
Orthopedic Medicine & Surgery (AREA)
Neurology (AREA)
Rheumatology (AREA)
Dermatology (AREA)
Heart & Thoracic Surgery (AREA)
Neurosurgery (AREA)
Obesity (AREA)
Urology & Nephrology (AREA)
Reproductive Health (AREA)
Epidemiology (AREA)
Biomedical Technology (AREA)
Pulmonology (AREA)
Emergency Medicine (AREA)
Hematology (AREA)
Vascular Medicine (AREA)
Transplantation (AREA)
Pain & Pain Management (AREA)
Ophthalmology & Optometry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)

ZA200109610A 1999-06-03 2001-11-21 Benzothiazinone and benzoxazinone compounds. ZA200109610B (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US13741099P	1999-06-03	1999-06-03

Publications (1)

Publication Number	Publication Date
ZA200109610B true ZA200109610B (en)	2003-04-30

Family

ID=22477310

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ZA200109610A ZA200109610B (en)	1999-06-03	2001-11-21	Benzothiazinone and benzoxazinone compounds.

Country Status (18)

Country	Link
US (1)	US7049312B1 (fr)
EP (1)	EP1181282A2 (fr)
JP (1)	JP2003501429A (fr)
KR (1)	KR20020062808A (fr)
CN (1)	CN1636005A (fr)
AR (1)	AR031830A1 (fr)
AU (1)	AU5179000A (fr)
BG (1)	BG106238A (fr)
BR (1)	BR0011063A (fr)
CA (1)	CA2375734A1 (fr)
CZ (1)	CZ20014244A3 (fr)
HK (1)	HK1046402A1 (fr)
IL (1)	IL146474A0 (fr)
MX (1)	MXPA01012442A (fr)
NO (1)	NO20015899L (fr)
PL (1)	PL352680A1 (fr)
WO (1)	WO2000075139A2 (fr)
ZA (1)	ZA200109610B (fr)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2004528335A (ja) *	2001-04-23	2004-09-16	アストラゼネカアクチボラグ	血管新生の治療に使用のベンゾオキサジノン誘導体
US7173128B2 (en)	2001-08-13	2007-02-06	Ciba Specialty Chemicals Corporation	Ultraviolet light absorbers
KR20040106451A (ko) *	2002-05-03	2004-12-17	쉐링 악티엔게젤샤프트	폴로-유사 키나제 억제제로서의 티아졸리디논 및 그의 용도
AR045037A1 (es)	2003-07-10	2005-10-12	Aventis Pharma Sa	Tetrahidro-1h-pirazolo [3,4-c] piridinas sustituidas, composiciones que las contienen y su utilizacion.
ES2527118T3 (es)	2003-12-19	2015-01-20	Plexxikon Inc.	Compuestos y procedimientos de desarrollo de moduladores de Ret
US7498342B2 (en)	2004-06-17	2009-03-03	Plexxikon, Inc.	Compounds modulating c-kit activity
JP2008520744A (ja) *	2004-11-19	2008-06-19	ザ・レジェンツ・オブ・ザ・ユニバーシティ・オブ・カリフォルニア	抗炎症性ピラゾロピリミジン
BRPI0606872A2 (pt) *	2005-01-28	2009-07-21	Novartis Ag	uso de pirimidilaminobenzamidas para o tratamento de doenças que respondem à modulação de atividade de tie-2 quinase
US8000981B2 (en)	2005-11-30	2011-08-16	The Invention Science Fund I, Llc	Methods and systems related to receiving nutraceutical associated information
US8068991B2 (en) *	2005-11-30	2011-11-29	The Invention Science Fund I, Llc	Systems and methods for transmitting pathogen related information and responding
US8340944B2 (en)	2005-11-30	2012-12-25	The Invention Science Fund I, Llc	Computational and/or control systems and methods related to nutraceutical agent selection and dosing
US10296720B2 (en)	2005-11-30	2019-05-21	Gearbox Llc	Computational systems and methods related to nutraceuticals
US7927787B2 (en)	2006-06-28	2011-04-19	The Invention Science Fund I, Llc	Methods and systems for analysis of nutraceutical associated components
US8297028B2 (en)	2006-06-14	2012-10-30	The Invention Science Fund I, Llc	Individualized pharmaceutical selection and packaging
US7827042B2 (en)	2005-11-30	2010-11-02	The Invention Science Fund I, Inc	Methods and systems related to transmission of nutraceutical associated information
US7974856B2 (en)	2005-11-30	2011-07-05	The Invention Science Fund I, Llc	Computational systems and methods related to nutraceuticals
AU2007347115A1 (en)	2006-04-04	2008-10-23	The Regents Of The University Of California	PI3 kinase antagonists
BRPI0711358A2 (pt)	2006-05-09	2011-09-27	Pfizer Prod Inc	derivados do ácido cicloalquilamino e suas composições farmacêuticas
JP2008231088A (ja) *	2006-10-30	2008-10-02	Santen Pharmaceut Co Ltd	１，４−ベンゾオキサジン−３−オン骨格を有する新規化合物
WO2008053863A1 (fr) *	2006-10-30	2008-05-08	Santen Pharmaceutical Co., Ltd.	Nouveau composé ayant un squelette de 1,4-benzothiazin-3-one ou un squelette de 3,4-dihydroquinolin-2-one
WO2008063888A2 (fr)	2006-11-22	2008-05-29	Plexxikon, Inc.	Composés modulant l'activité de c-fms et/ou de c-kit et utilisations associées
FR2913019A1 (fr) *	2007-02-23	2008-08-29	Cerep Sa	Composes heterocycliques comme agents anti-neoplasiques ou inhibiteurs de proliferation cellulaire
SG183036A1 (en)	2007-07-17	2012-08-30	Plexxikon Inc	Compounds and methods for kinase modulation, and indications therefor
GB2467670B (en)	2007-10-04	2012-08-01	Intellikine Inc	Chemical entities and therapeutic uses thereof
US8193182B2 (en)	2008-01-04	2012-06-05	Intellikine, Inc.	Substituted isoquinolin-1(2H)-ones, and methods of use thereof
DK2240451T3 (da)	2008-01-04	2017-11-20	Intellikine Llc	Isoquinolinonderivater substitueret med en purin, der er anvendelig som pi3k-inhibitorer
US8637542B2 (en) *	2008-03-14	2014-01-28	Intellikine, Inc.	Kinase inhibitors and methods of use
US8993580B2 (en)	2008-03-14	2015-03-31	Intellikine Llc	Benzothiazole kinase inhibitors and methods of use
CN103709148B (zh) *	2008-06-24	2015-10-21	霍夫曼-拉罗奇有限公司	取代的吡啶-2-酮和哒嗪-3-酮
BRPI0915231A2 (pt)	2008-07-08	2018-06-12	Intellikine Inc	compostos inibidores de quinase e métodos de uso
US20110224223A1 (en)	2008-07-08	2011-09-15	The Regents Of The University Of California, A California Corporation	MTOR Modulators and Uses Thereof
EP2328877A4 (fr) *	2008-08-15	2011-08-24	Univ Texas	Composés de 1,4-benzoxazine, et dérivés de ceux-ci en tant que médicaments thérapeutiques pour le traitement de troubles neurodégénératifs
CA2738429C (fr)	2008-09-26	2016-10-25	Intellikine, Inc.	Inhibiteurs heterocycliques de kinases
CA2740885C (fr)	2008-10-16	2018-04-03	The Regents Of The University Of California	Inhibiteurs d'heteroarylkinase a noyau fusionne
US8476282B2 (en)	2008-11-03	2013-07-02	Intellikine Llc	Benzoxazole kinase inhibitors and methods of use
WO2010077680A2 (fr)	2008-12-08	2010-07-08	Vm Discovery Inc.	Compositions d'inhibiteurs de tyrosine kinase de récepteur protéique
EA022924B1 (ru)	2009-04-03	2016-03-31	Ф.Хоффманн-Ля Рош Аг	ТВЁРДАЯ ФОРМА {3-[5-(4-ХЛОРФЕНИЛ)-1Н-ПИРРОЛО[2,3-b]ПИРИДИН-3-КАРБОНИЛ]-2,4-ДИФТОРФЕНИЛ}АМИДА ПРОПАН-1-СУЛЬФОНОВОЙ КИСЛОТЫ И ЕЁ ПРИМЕНЕНИЕ
EP2427195B1 (fr)	2009-05-07	2019-05-01	Intellikine, LLC	Composés hétérocycliques et leurs utilisations
WO2011047384A2 (fr)	2009-10-16	2011-04-21	The Regents Of The University Of California	Procédés d'inhibition de l'activité ire1
MA33975B1 (fr)	2009-11-06	2013-02-01	Plexxikon Inc	Composés et méthodes de modulation des kinases et leurs indications d'emploi
JP5656233B2 (ja)	2010-04-30	2015-01-21	国立大学法人東京大学	抗がん剤
AU2011255218B2 (en)	2010-05-21	2015-03-12	Infinity Pharmaceuticals, Inc.	Chemical compounds, compositions and methods for kinase modulation
AU2011326427B2 (en)	2010-11-10	2016-01-07	Infinity Pharmaceuticals Inc.	Heterocyclic compounds and uses thereof
PE20180318A1 (es)	2011-01-10	2018-02-09	Infinity Pharmaceuticals Inc	Procedimiento para preparar isoquinolinonas y formas solidas de isoquinolinonas
JP5941069B2 (ja)	2011-02-07	2016-06-29	プレキシコンインコーポレーテッドＰｌｅｘｘｉｋｏｎＩｎｃ．	キナーゼ調節のための化合物および方法、ならびにそれに対する適応症
TWI558702B (zh)	2011-02-21	2016-11-21	普雷辛肯公司	醫藥活性物質的固態形式
JP6130305B2 (ja)	2011-02-23	2017-05-17	インテリカイン，エルエルシー	キナーゼ阻害剤の組み合わせおよびそれらの使用
CN103747787A (zh) *	2011-05-27	2014-04-23	坦普尔大学	取代的2-亚苄基-2H-苯并[b][1,4]噻嗪-3(4H)-酮类、其衍生物及其治疗应用
WO2013012918A1 (fr)	2011-07-19	2013-01-24	Infinity Pharmaceuticals Inc.	Composés hétérocycliques et leurs utilisations
WO2013012915A1 (fr)	2011-07-19	2013-01-24	Infinity Pharmaceuticals Inc.	Composés hétérocycliques et leurs utilisations
AR091790A1 (es)	2011-08-29	2015-03-04	Infinity Pharmaceuticals Inc	Derivados de isoquinolin-1-ona y sus usos
JP6342805B2 (ja)	2011-09-02	2018-06-13	ザリージェンツオブザユニバーシティオブカリフォルニア	置換ピラゾロ［３，４−ｄ］ピリミジンおよびその用途
US8940742B2 (en)	2012-04-10	2015-01-27	Infinity Pharmaceuticals, Inc.	Heterocyclic compounds and uses thereof
US9150570B2 (en)	2012-05-31	2015-10-06	Plexxikon Inc.	Synthesis of heterocyclic compounds
BR112014029705A2 (pt) *	2012-06-01	2017-06-27	Takeda Pharmaceuticals Co	composto ou sal, medicamento, métodos para inibir quinase de janus em um mamífero, e para a profilaxia ou tratamento de doenças autoimunes, e, uso de um composto ou sal
US8828998B2 (en)	2012-06-25	2014-09-09	Infinity Pharmaceuticals, Inc.	Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
WO2014011754A1 (fr) *	2012-07-10	2014-01-16	Amir Tamiz	Nouveaux composés de 1,4-benzoxazinone
KR20150061651A (ko)	2012-09-26	2015-06-04	더 리젠츠 오브 더 유니버시티 오브 캘리포니아	Ire1의 조절
MX2015004615A (es) *	2012-10-16	2015-07-17	Hoffmann La Roche	Inhibidores de serina/treonina cinasa.
LT2914296T (lt)	2012-11-01	2018-09-25	Infinity Pharmaceuticals, Inc.	Vėžio gydymas, panaudojant p13 kinazės izoformos moduliatorius
US8999992B2 (en)	2013-03-15	2015-04-07	Vm Pharma Llc	Crystalline forms of tryosine kinase inhibitors and their salts
US9481667B2 (en)	2013-03-15	2016-11-01	Infinity Pharmaceuticals, Inc.	Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
AU2014234908B2 (en) *	2013-03-19	2017-08-17	Merck Sharp & Dohme Corp.	N-(2-cyano heterocyclyl)pyrazolo pyridones as Janus kinase inhibitors
US9751888B2 (en)	2013-10-04	2017-09-05	Infinity Pharmaceuticals, Inc.	Heterocyclic compounds and uses thereof
WO2015051244A1 (fr)	2013-10-04	2015-04-09	Infinity Pharmaceuticals, Inc.	Composés hétérocycliques et leurs utilisations
CN103755659B (zh) *	2014-02-25	2015-07-15	山东大学	6-肉桂酰基-2H-苯并[b][1,4]噁嗪-3(4H)-酮类化合物及其应用
EP3119397B1 (fr)	2014-03-19	2022-03-09	Infinity Pharmaceuticals, Inc.	Composés hétérocycliques destinés à être utilisés dans le traitement de troubles médiés par pi3k-gamma
US20150320755A1 (en)	2014-04-16	2015-11-12	Infinity Pharmaceuticals, Inc.	Combination therapies
MA39286A (fr)	2014-09-17	2016-03-24	Mundipharma International Corporation Ltd	Formes cristallines d'inhibiteurs de la tyrosine kinase et leurs sels
WO2016054491A1 (fr)	2014-10-03	2016-04-07	Infinity Pharmaceuticals, Inc.	Composés hétérocycliques et leurs utilisations
CN114230571B (zh)	2015-09-14	2025-07-08	无限药品股份有限公司	异喹啉酮的固体形式、其制备方法、包含其的组合物及其使用方法
US10759806B2 (en)	2016-03-17	2020-09-01	Infinity Pharmaceuticals, Inc.	Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as PI3K kinase inhibitors
US10919914B2 (en)	2016-06-08	2021-02-16	Infinity Pharmaceuticals, Inc.	Heterocyclic compounds and uses thereof
UA125216C2 (uk)	2016-06-24	2022-02-02	Інфініті Фармасьютікалз, Інк.	Комбінована терапія
US11332466B2 (en) *	2017-12-01	2022-05-17	The Board Of Trustees Of The University Of Illinois	Pyridinone-based epigenetic modifiers and uses thereof
CA3192617A1 (fr) *	2020-09-20	2022-03-24	Matthew BAGGOTT	Compositions de tryptamine avantageuses pour troubles mentaux ou amelioration mentale
CN114601825B (zh) *	2022-02-18	2023-08-04	复旦大学附属中山医院	一种肠道菌群代谢物吲哚-3-甲醛在防治动脉粥样硬化中的应用
US11780838B1 (en)	2023-03-23	2023-10-10	King Faisal University	Pyrrolo[3,2-b]quinoline compounds as antibacterial agents

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3635956A (en)	1968-03-01	1972-01-18	Squibb & Sons Inc	Benzothiazines related compounds derivatives and salts thereof
DE2051474A1 (de) *	1969-10-28	1971-05-06	ER Squibb & Sons Ine , New York, N Y (V St A )	Heterocyclische Verbindungen, ihre Salze, Verfahren zu ihrer Herstellung und ihre Verwendung
US3812114A (en)	1971-09-29	1974-05-21	Squibb & Sons Inc	Benzothiazines
US3865818A (en) *	1973-10-24	1975-02-11	Squibb & Sons Inc	Substituted benzoxazines
US3923709A (en)	1974-08-30	1975-12-02	Monsanto Co	3,4-Dihydro-3-oxo-2H-1,4-benzothiazines and benzoxazines
JPS6072875A (ja) *	1983-09-28	1985-04-24	Hamari Yakuhin Kogyo Kk	１，５−ベンゾチアゼピン誘導体およびその製造法
US4490292A (en) *	1983-10-07	1984-12-25	Hamari Chemicals, Ltd.	1,5-Benzothiazepine derivatives and production thereof
JPS61229874A (ja) *	1985-04-03	1986-10-14	Toubishi Yakuhin Kogyo Kk	ベンゾチアジン誘導体の製造方法
DE69329618T2 (de) *	1992-08-31	2001-05-17	Santen Pharmaceutical Co., Ltd	3-oxo-1,4-benzothiazin-derivate
WO1995013269A1 (fr) *	1993-11-12	1995-05-18	Santen Pharmaceutical Co., Ltd.	Derive de 1,4-benzothiazine

2000
- 2000-06-02 CZ CZ20014244A patent/CZ20014244A3/cs unknown
- 2000-06-02 MX MXPA01012442A patent/MXPA01012442A/es unknown
- 2000-06-02 PL PL00352680A patent/PL352680A1/xx not_active Application Discontinuation
- 2000-06-02 EP EP00936476A patent/EP1181282A2/fr not_active Withdrawn
- 2000-06-02 CA CA002375734A patent/CA2375734A1/fr not_active Abandoned
- 2000-06-02 US US09/585,925 patent/US7049312B1/en not_active Expired - Lifetime
- 2000-06-02 BR BR0011063-9A patent/BR0011063A/pt not_active Application Discontinuation
- 2000-06-02 WO PCT/US2000/015324 patent/WO2000075139A2/fr not_active Ceased
- 2000-06-02 IL IL14647400A patent/IL146474A0/xx unknown
- 2000-06-02 HK HK02106280.4A patent/HK1046402A1/zh unknown
- 2000-06-02 AU AU51790/00A patent/AU5179000A/en not_active Abandoned
- 2000-06-02 KR KR1020017015588A patent/KR20020062808A/ko not_active Withdrawn
- 2000-06-02 JP JP2001502421A patent/JP2003501429A/ja not_active Withdrawn
- 2000-06-02 CN CNA008111138A patent/CN1636005A/zh active Pending
- 2000-06-05 AR ARP000102783A patent/AR031830A1/es unknown
2001
- 2001-11-21 ZA ZA200109610A patent/ZA200109610B/xx unknown
- 2001-12-03 NO NO20015899A patent/NO20015899L/no not_active Application Discontinuation
- 2001-12-19 BG BG106238A patent/BG106238A/xx unknown

Also Published As

Publication number	Publication date
PL352680A1 (en)	2003-09-08
WO2000075139A2 (fr)	2000-12-14
CA2375734A1 (fr)	2000-12-14
BR0011063A (pt)	2002-04-16
KR20020062808A (ko)	2002-07-31
NO20015899L (no)	2002-01-30
EP1181282A2 (fr)	2002-02-27
AR031830A1 (es)	2003-10-08
AU5179000A (en)	2000-12-28
NO20015899D0 (no)	2001-12-03
HK1046402A1 (zh)	2003-01-10
JP2003501429A (ja)	2003-01-14
WO2000075139A3 (fr)	2001-03-29
US7049312B1 (en)	2006-05-23
BG106238A (en)	2002-08-30
MXPA01012442A (es)	2004-09-10
CN1636005A (zh)	2005-07-06
IL146474A0 (en)	2002-07-25
CZ20014244A3 (cs)	2002-07-17

Publication	Publication Date	Title
ZA200109610B (en)	2003-04-30	Benzothiazinone and benzoxazinone compounds.
MXPA01013362A (es)	2003-09-04	Anticuerpos de humano, anti-alfavbeta3 recombinantes, °cidos nucleicos que codifican a los mismos y metodos de uso.
EG24743A (en)	2010-07-14	Heterocyclic compounds.
ZA200200477B (en)	2003-06-25	2-pyrazolin-5-ones.
EG24361A (en)	2009-03-04	4-pyrimiding1-n-acy1.l.phenlalanines
ZA200000894B (en)	2000-08-24	4-Phenyl-pyridine derivatives.
ZA200201055B (en)	2003-07-30	Amino-triazolopyridine derivatives.
ZA200202537B (en)	2003-09-23	Pour-on-formulations.
ZA200201829B (en)	2003-08-27	New phenylpiperazines.
ZA200109595B (en)	2003-05-28	13-methyl-erythromycin derivatives.
ZA200000865B (en)	2001-04-06	Dicarboalkoxy dioxolanes.
ZA200203762B (en)	2004-01-28	4-pyridinyl-IN-acyl-L-phenylalanines.
ZA200108968B (en)	2003-09-05	New compounds.
ZA200204325B (en)	2003-11-26	Area Denial.
MXPA02001506A (es)	2003-07-21	Unidad de boton.
ZA200006206B (en)	2001-06-25	Benzazole compounds and their use.
ZA200108489B (en)	2003-03-26	Tampon.
ZA200201276B (en)	2003-07-30	3-Amino-2-phenyl-propane derivatives.
MXPA02000261A (es)	2003-08-20	Aminoindanos novedosos.
MXPA01011570A (es)	2003-08-20	Gen derivado de lawsonia y polipeptidos, peptidos y proteinas relacionadas con peptido h de membrana externa.
GB0029720D0 (en)	2001-01-17	I.S machine7544232001
MXPA01011285A (es)	2003-09-04	Derivados de tio-oxindol.
ZA200204581B (en)	2003-08-27	Nitro-sulfobenzamides.
ZA985938B (en)	2000-01-10	Epothilone derivatives.
MXPA02003911A (es)	2003-09-25	CUnA PARA EVITAR CONTRAGIRO.